Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Corporate profile

Grünenthal is a global leader in pain management and related diseases.

We have a long track record of bringing innovative treatments to patients worldwide. As a fully integrated pharmaceutical company, we cover the entire value chain – from drug research and development to commercialisation of portfolios with growth products and established medicines. We operate in accordance with the highest ethical and regulatory standards. At Grünenthal, we focus our efforts on our vision of a World Free of Pain.

Grünenthal at a glance

Our virtual company showcase provides information about our key objectives and activities, as well as our recent business development highlights and financial performance.

Enter

keywords

Strong and capable team

4,300

employees worldwide

Solid revenue base

1.8

billion euros in 2024

Commercial presence in

28

countries across Europe, Latin America, and the US

Products sold in around

100

countries

International network

2

R&D sites – one R&D Unit in Aachen (Germany) and an Innovation Hub in Boston, (USA)

Production capacities

5

manufacturing sites in Europe and Latin America

Elderly female patient with crutches

Our unique commitment

For over 50 years, we have been a pioneer in pain treatments, tackling critical unmet medical needs and bringing us closer to our vision of a World Free of Pain.

A World Free of Pain

MSCI recognises Grünenthal as an ESG industry leader" role. MSCI Provisional ESG Ratings (p)AA as of Oct. 2024

ESG Industry Leader

At Grünenthal, conducting our business responsibly is an integral part of our company’s strategy and culture. We aspire to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards. Our industry-leading way of doing business responsibly is reflected in our external Environment, Social and Governance (ESG) ratings.

Contract Manufacturing GRT PRO

Global capabilities

Grünenthal operates five world-class manufacturing sites around the globe, where we produce all of our own products, as well as manufacturing medicines for key industry partners. We have made significant investments into our facilities and are fully committed to ensuring the quality, safety and sustainability of every medicine we produce for patients.

Presence & Sites

Pipeline

Pipeline

Our scientists have developed several life-changing pain medicines for patients. To move closer to our vision of a World Free of Pain, we are pursuing a range of programs across different modalities, targets, and mechanisms of action.

Development Pipeline